Immunotherapy strategies across bladder cancer continuum

Apolo highlighted the positive topline results from the phase 3 EV-303 trial (NCT03924895) evaluating EV plus pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer.

Christof Vulsteke, MD, PhD, discusses results from the KEYNOTE-905 trial, evaluating perioperative EV/pembrolizumab in cisplatin-ineligible MIBC.

Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025.

Joshua J. Meeks, MD, PhD, highlights that collaboration between urologists and medical oncologists has become essential.

One particularly striking finding from KEYNOTE-905/EV-303 is the nearly 60% pathologic complete response rate.

At the 2025 LUGPA Annual Meeting, Joshua J. Meeks, MD, PhD, outlined the rapidly evolving treatment landscape in MIBC.

Fed Ghali, MD, discusses the potential opportunity to de-escalate therapy in patients receiving perioperative EV/pembro.

Daneshmand also emphasized the evolving, highly collaborative role between urologists and medical oncologists as perioperative systemic regimens expand.

The combination yielded significant improvements in event-free survival, overall survival, and pathologic complete response rates vs neoadjuvant chemotherapy.